Gilead’s rheumatoid arthritis pill approved in JapanGilead has scored a major approval for its troubled rheumatoid arthritis pill filgotinib, after regulators in Japan granted Share XGilead’s rheumatoid arthritis pill approved in Japanhttps://pharmaphorum.com/news/gileads-rheumatoid-arthritis-pill-approved-in-japan/
Japan trials app to help coronavirus patients recover at homeA smartphone app developed by medical software specialist Allm is being trialled in Japan to see if it Share XJapan trials app to help coronavirus patients recover at homehttps://pharmaphorum.com/news/japan-trials-app-to-help-coronavirus-patients-recover-at-home/
Biogen and Eisai trial drug in asymptomatic Alzheimer’s diseaseBiogen and Eisai have begun a new phase 3 study testing an Alzheimer’s antibody drug aimed at patients without symptoms but Share XBiogen and Eisai trial drug in asymptomatic Alzheimer’s diseasehttps://pharmaphorum.com/news/biogen-and-eisai-trial-drug-in-asymptomatic-alzheimers-disease/
Biogen shares pop as it completes filing for Alzheimer’s drug aducanumabBiogen’s share price was up sharply on Wednesday after the big pharma completed its filing of its Alzheimer’s Share XBiogen shares pop as it completes filing for Alzheimer’s drug aducanumabhttps://pharmaphorum.com/news/biogen-shares-pop-as-it-completes-filing-for-alzheimers-drug-aducanumab/
Chasing Merck, Eisai launches insomnia drug Dayvigo in JapanEisai has launched its insomnia drug Dayvigo in Japan, the second in a new class of medicines after Share XChasing Merck, Eisai launches insomnia drug Dayvigo in Japanhttps://pharmaphorum.com/news/chasing-merck-eisai-launches-insomnia-drug-dayvigo-in-japan/
Idorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winSwitzerland’s Idorsia says it is on course to file a potential next-generation insomnia drug around the end of this year after a Share XIdorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winhttps://pharmaphorum.com/news/idorsia-on-course-to-take-on-eisai-and-merck-co-after-latest-insomnia-phase-3-trial-win/
Eisai and Alexa skills in epilepsy: the pharmaphorum podcastVoice technology like Amazon’s Alexa is taking some big steps forward in healthcare and in the pharmaceutical world Share XEisai and Alexa skills in epilepsy: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/eisai-alexa-skills-epilepsy/
Pharma giants including Novartis collaborate on COVID-19 therapiesA consortium of life sciences companies including pharma giants such as Novartis and Johnson & Johnson, are to Share XPharma giants including Novartis collaborate on COVID-19 therapieshttps://pharmaphorum.com/news/collaborate-covid19-therapies/
FDA clears Eisai’s insomnia drug DayvigoThe FDA’s traditional last-minute flurry of approvals as the year heads to a close included Eisai’s Dayvigo, a Share XFDA clears Eisai’s insomnia drug Dayvigohttps://pharmaphorum.com/news/fda-clears-eisais-insomnia-drug-dayvigo/
